SharkNinja, Inc. (SN) research: valuation against peers, fundamentals over time, risk and news coverage

SN

SharkNinja, Inc.
USD
180.76
+0.43% today
Market cap
P/E trailing
P/E forward
EV/EBITDA
Op margin
Rev growth
Div yield
Beta
52-week range84.57188.593 report(s) in our archive
Price navigator — SN

No data in this window.

    INDY NEWS coverage of SN3

    Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.

    • SPECIAL REPORTBEARISH
      Insider Selling Wave Broadens Across Mid-Cap America as Executives Cash Into Strength

      A dense cluster of Form 4 disclosures spanning healthcare services, consumer retail, diagnostics, consumer durables and software points to coordinated executive de-risking into post-earnings rallies. Encompass Health saw three separate insiders sell after a rate increase, with the CFO cutting his direct common position 27% and CEO Mark Tarr trimming while retaining roughly 268,000 shares worth $33.7 million.

    • BREAKING STORYBEARISH
      Analyst Desks Fan Out Across Biotech and Consumer as China Auto Demand Cracks

      Sell-side research activity clustered in clinical-stage biotech and consumer discretionary names, with upgrades for ConocoPhillips, SharkNinja, BridgeBio and Cogent offset by reductions at Middleby and Neurogene. The sharper signal came from China, where July passenger vehicle retail sales fell 20% year over year.

    • MARKET REPORTNEUTRAL
      SharkNinja CEO sells nearly 600,000 shares in transaction valued above $100 million

      Mark Barrocas, chief executive of SharkNinja, disclosed the sale of close to 600,000 shares worth more than $100 million, following a roughly 61% one-year gain in the stock.

    Full archive search for SN

    Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.